RxDoctor Payments Data

Steven Levine

Interventional Cardiology · Santa Monica, CANPI 1841225950

Payments from drug & device makers

$222in general payments, 2019–2025

Across 10 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$43
  • Kowa Pharmaceuticals America, Inc.$27
  • E.r. Squibb & Sons, L.L.C.$25
  • Abiomed$25
  • Novo Nordisk$23
  • Johnson & Johnson$23
  • plus $55 from 3 others

What the payments were for

  • Food & beverage$222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie2$43
Kowa Pharmaceuticals America, Inc.1$27
E.r. Squibb & Sons, L.L.C.1$25
Abiomed1$25
Novo Nordisk1$23
Johnson & Johnson1$23
Abbott1$21
Amgen1$18
Bardy Diagnostics, Inc.1$16

How this compares

$222 in reported general payments places this provider in the 5th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$685,213
Medicare patients
475
Services billed
7,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban443$369,280
VyndamaxTafamidis12$262,116
Repatha SureclickEvolocumab369$246,022
EntrestoSacubitril/Valsartan143$119,641
JardianceEmpagliflozin102$81,333
FarxigaDapagliflozin Propanediol88$57,982
VascepaIcosapent Ethyl50$26,864
OzempicSemaglutide18$24,831
XareltoRivaroxaban21$23,143
Praluent PenAlirocumab22$20,664
MounjaroTirzepatide15$17,782
BrilintaTicagrelor12$12,829
Nebivolol Hcl143$9,259
Colchicine124$7,384
Rosuvastatin Calcium449$6,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$24,83118 claims
Johnson & JohnsonXarelto$23$23,14321 claims
AbbVieSynthroid$43$65913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →